Tech Company Financing Transactions
QL Biopharm Funding Round
QL Biopharm, based in Beijing, secured $72 million in funding from OrbiMed, BlueRun Ventures and Huagai Capital.
Transaction Overview
Company Name
Announced On
3/2/2026
Transaction Type
Venture Equity
Amount
$72,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 7, No. 20, Life Science Park Road, Changping Distri 101
Beijing, 102206
China
Beijing, 102206
China
Phone
Undisclosed
Website
Email Address
Overview
Founded in September 2018, Tripeptide Biotech focuses on producing recombinant protein drugs using E. coli and is committed to developing innovative biopharmaceuticals to treat chronic metabolic diseases (such as diabetes, obesity, and non-alcoholic steatohepatitis) and improve people's quality of life. Currently, the biopeptide pipeline has 10 recombinant protein innovative drugs and biosimilars under development, including two independently developed Class I innovative drugs and one domestically produced international blockbuster biosimilar that has entered the clinical trial stage. The core members of the Peptide Biotechnology R&D team come from well-known domestic and international pharmaceutical companies such as Novo Nordisk, Bayer, and Gan & Lee, and have accumulated extensive experience in biopharmaceuticals. The company currently possesses a complete industry chain from drug development and pilot-scale amplification to commercialization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zhang Xujia
Chief Operating Officer
Wu Ning
Co-Founder
Zhai Peng
Browse more venture capital transactions:
Prev: 3/2/2026: Skema.ai venture capital transaction
Next: 3/2/2026: Ease Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs